Get the Stockscreener App
207.88
0.74%
-1.55
After Hours:
207.88
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $207.88, with a volume of 1.85M.
It is down -0.74% in the last 24 hours and down -7.23% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$209.43
Open:
$211
24h Volume:
1.85M
Relative Volume:
1.56
Market Cap:
$30.15B
Revenue:
$5.40B
Net Income/Loss:
$1.49B
P/E Ratio:
20.55
EPS:
10.1168
Net Cash Flow:
$1.78B
1W Performance:
-4.26%
1M Performance:
-7.23%
6M Performance:
-15.23%
1Y Performance:
-13.62%
1-Day Range:
$205.94
$211.00
1-Week Range:
$198.64
$216.59
52-Week Range:
$198.64
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
207.88 | 30.38B | 5.40B | 1.49B | 1.78B | 10.12 |
ISRG
Intuitive Surgical Inc
|
451.38 | 160.21B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.17 | 41.62B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
45.32 | 37.37B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
74.45 | 35.82B | 10.40B | 980.00M | 1.61B | 1.9749 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed, Inc. Hits New 52-Week Low at USD 210.67 - Markets Mojo
Resmed enters merger agreement to acquire Noctrix Health for $340 million - MassDevice
9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time - Investing.com
Resmed integrating AI for sleep apnea treatment - Fox Business
Birch Capital Management LLC Reduces Stock Holdings in ResMed Inc. $RMD - MarketBeat
Stifel Nicolaus Adjusts ResMed Price Target to $235 From $265 - Moomoo
Ord Minnett Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
[Form 3] RESMED INC Initial Statement of Beneficial Ownership - Stock Titan
ResMed (RMD) CFO Brett Sandercock reports direct holding of 83,495 shares - Stock Titan
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed (RMD) Is Down 6.7% After Earnings Beat And CFO Transition NewsWhat's Changed - Sahm
ResMed Price Target Cut 13% to A$41.72/Share by Morgans - Moomoo
CSL, Resmed, Cochlear Lead Losses on ASX - marketscreener.com
ResMed Price Target Cut 2% to A$46.50/Share by Macquarie - Moomoo
ResMed Updates CDI Count Amid Routine Share Transfers, Issuances and Buybacks - TipRanks
ResMed: Q3 result 2026 - intelligentinvestor.com.au
ResMed Inc. 2026 Q3ResultsEarnings Call Presentation (NYSE:RMD) 2026-05-03 - Seeking Alpha
ResMed Files March 2026 Quarterly Report Detailing Capital Structure and Compliance Status - TipRanks
ResMed expects FY 2026 gross margin of 62%-63% as it plans $175M+ Q4 buybacks and targets June 1 close for $340M Noctrix deal - MSN
ResMed (RMD) Margin Strength At 27.5% Tests Bearish Cost And GLP 1 Narratives - Sahm
ResMed Stock Fell 8% This Week. Here’s What a Strong Earnings Beat Means for the Recovery Case - TIKR.com
Why ResMed (RMD) Narrative Is Shifting As Analysts Reassess Growth And Valuation Assumptions - Yahoo Finance
Pittenger & Anderson Inc. Acquires 5,421 Shares of ResMed Inc. $RMD - MarketBeat
PFA Pension Forsikringsaktieselskab Buys Shares of 188,393 ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Stake Cut by Danske Bank A S - MarketBeat
ResMed Shifts Leadership And Adds Neurology With Noctrix Acquisition - Sahm
ResMed: Stock splutters, but machine is still breathing well - marketscreener.com
Should you continue to hold Resmed stock in your portfolio? - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Immunome (IMNM) and Resmed (RMD) - The Globe and Mail
ResMed Q3 Earnings Call Highlights - Yahoo Finance
Pictet Asset Management Holding SA Sells 42,929 Shares of ResMed Inc. $RMD - MarketBeat
ResMed stock hits 52-week low at $205.86 amid market challenges - Investing.com Nigeria
Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Resmed (RMD) - The Globe and Mail
ResMed Earnings Call Highlights Margin Strength, Growth - TipRanks
ResMed Inc (RMD) Stock Down 4.1% -- Now Undervalued? GF Score: 9 - GuruFocus
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
ResMed on Track for Lowest Close Since July 2024 -- Data Talk - Moomoo
Royal Bank Of Canada Forecasts Strong Price Appreciation for ResMed (NYSE:RMD) Stock - MarketBeat
ResMed Q3 2026 earnings preview - MSN
ResMed (NYSE:RMD) Shares Down 6% on Analyst Downgrade - MarketBeat
Resmed’s 20-Year CFO Brett Sandercock Announces Retirement - Medical Product Outsourcing
ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets - Morningstar
Wells Fargo & Company Issues Pessimistic Forecast for ResMed (NYSE:RMD) Stock Price - MarketBeat
ResMed Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Mizuho Securities Adjusts ResMed Price Target to $235 From $255, Maintains Outperform Rating - marketscreener.com
RBC Raises Price Target on ResMed to $321 From $314, Keeps Outperform Rating - marketscreener.com
ResMed Inc. (NYSE:RMD) Plans Quarterly Dividend of $0.60 - MarketBeat
Jefferies Adjusts ResMed Price Target to $240 From $290 - marketscreener.com
ResMed Inc. (NYSE:RMD) Q3 2026 Earnings Call Transcript - Insider Monkey
Wells Fargo Adjusts ResMed Price Target to $227 From $270 - marketscreener.com
Baird Adjusts ResMed Price Target to $225 From $254 - marketscreener.com
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):